Recursion completes its combination with Exscientia

Background

The combination was announced in August 2024. Reuters and CNBC reported its value at $688 million, although the two companies never formally disclosed a figure.^[1] Both Recursion and Exscientia are associated with the use of computational methods in drug discovery, and the transaction joined a North American company with a European one.^[1]

In a business combination of this shape, one company ends up owning the other outright, and the acquired firm continues as a wholly-owned subsidiary rather than being dissolved. That structure matters for a research organisation: individual programmes, laboratory sites and scientific staff can be carried over intact, while budgets, reporting lines and executive responsibility are consolidated at the top.

The close

Recursion completed the business combination on 20 November 2024, and Exscientia became a wholly-owned subsidiary.^[1][2] The closing turned what had been an announced intention over the summer into a single company with one management team and one portfolio.

What the combined company looks like

At the close, the combined company reported a pipeline of more than 10 clinical and preclinical programmes, 10 programmes in advanced discovery, and more than 10 programmes partnered with biopharma companies.^[1] Those three groups are counted separately — clinical and preclinical assets, discovery-stage projects, and partnered work — so the totals overlap rather than adding up to a single number of drugs.

Headcount fell to roughly 800 from about 900 before the combination.^[1] The company reported about $576.6 million in cash and equivalents as of 30 September 2024,^[1] and it expected around $100 million of annual savings from the integration.^[1] Cash and integration savings are different kinds of number: the first is what was on hand at a point in time, the second is an estimate of what the merged organisation expects to spend less each year.

The headquarters remained in Salt Lake City, with primary offices in Toronto, Montreal, Milpitas, New York, London and Oxford.^[1] Chris Gibson remained chief executive, and Exscientia's Dave Hallett became chief scientific officer.^[1]

The furthest-along asset in oncology was REC-617, an Exscientia-developed CDK7 inhibitor.^[1] CDK7 is a kinase — an enzyme that attaches phosphate groups to other proteins — and it sits at the point where cells commit to transcribing genes, so blocking it is studied as a way to disrupt the growth of tumour cells.

Why it matters

The transaction is one of the clearest examples of consolidation among companies that apply machine learning and automated experimentation to drug discovery. Rather than competing for the same partners and investors, two of the better-known names in that field became one organisation, with a combined portfolio and a single balance sheet.

The details reported at the close show what that consolidation looked like in practice: a smaller workforce than the two companies had separately, a cash position of roughly $0.58 billion, and a stated expectation of about $100 million in annual savings from combining operations.^[1] They also show where the merged company chose to keep its scientific presence — a headquarters in Utah, offices in Canada, California, New York and the United Kingdom — and how it divided responsibility between the two former organisations, with Recursion's chief executive staying in place and Exscientia's scientific leadership taking the chief scientific officer role.^[1]

For observers of AI-driven drug discovery, the completed combination is a concrete data point about how the field's early companies are maturing: the question they face is no longer only whether a computational platform can generate candidate molecules, but whether an organisation can carry enough programmes, partners and cash at the same time to move them through clinical testing.